{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:08:23Z","timestamp":1786410503208,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias","award":["FIS 08\/1775"],"award-info":[{"award-number":["FIS 08\/1775"]}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.eimc.2016.02.010","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T03:34:56Z","timestamp":1458790496000},"page":"278-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Antimicrobial susceptibility of 6 antimicrobial agents in  Helicobacter pylori  clinical isolates by using EUCAST breakpoints compared with previously used breakpoints"],"prefix":"10.1016","volume":"35","author":[{"given":"Teresa","family":"Alarc\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Urruzuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Josefa","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"L\u00f3pez-Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2016.02.010_bib0110","first-page":"8979","article-title":"Helicobacter pylori: friend or foe?","volume":"20","author":"Malnick","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eimc.2016.02.010_bib0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrgastro.2013.243","article-title":"Clinical effects of Helicobacter pylori outside the stomach","volume":"11","author":"Franceschi","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eimc.2016.02.010_bib0120","first-page":"8971","article-title":"Natural products and food components with anti-Helicobacter pylori activities","volume":"20","author":"Takeuchi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eimc.2016.02.010_bib0125","doi-asserted-by":"crossref","first-page":"9898","DOI":"10.3748\/wjg.v20.i29.9898","article-title":"Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance","volume":"20","author":"Papastergiou","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eimc.2016.02.010_bib0130","series-title":"Performance standards for antimicrobial susceptibility testing: ninth informational supplement. Edition: Approved Standard M100-S9","author":"National Committee for Clinical Laboratory Standards","year":"1999"},{"issue":"Suppl. 1","key":"10.1016\/j.eimc.2016.02.010_bib0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/48.suppl_1.77","article-title":"Recommendations for susceptibility tests on fastidious organisms and those requiring special handling","volume":"48","author":"King","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10096-002-0757-6","article-title":"Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori","volume":"21","author":"Glupczynski","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2016.02.010_bib0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0150","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST Clinical Breakpoint Table v. 5.0, valid from 2015-01-01; http:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"10.1016\/j.eimc.2016.02.010_bib0155","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jac\/dkr524","article-title":"Effects of clinical breakpoint changes in CLSI guidelines 2010\/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli","volume":"67","author":"Hombach","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jac\/49.3.541","article-title":"In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults","volume":"49","author":"Fujimura","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0165","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/jac\/dkt061","article-title":"High secondary-resistance to quinolones in German Helicobacter pylori clinical isolates","volume":"68","author":"Wueppenhorst","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0170","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1017\/S0950268810001226","article-title":"Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area","volume":"139","author":"Yakoob","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.eimc.2016.02.010_bib0175","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/00365521.2014.887765","article-title":"Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis","volume":"49","author":"Xiao","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.eimc.2016.02.010_bib0180","doi-asserted-by":"crossref","first-page":"E466","DOI":"10.1111\/j.1469-0691.2012.03996.x","article-title":"Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia","volume":"18","author":"van der Bij","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2016.02.010_bib0185","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/AAC.48.12.4843-4847.2004","article-title":"Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea","volume":"48","author":"Kim","year":"2004","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/46.1.121","article-title":"Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin","volume":"46","author":"Wu","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.02.010_bib0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.eimc.2016.02.010_bib0200","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s15010-009-7108-9","article-title":"A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints","volume":"37","author":"Dalhoff","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.eimc.2016.02.010_bib0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2016.02.010_bib0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/23744235.2015.1082035","article-title":"Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria","volume":"48","author":"Boyanova","year":"2016","journal-title":"Infect Dis (Lond)"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X1600080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X1600080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T13:21:56Z","timestamp":1530019316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X1600080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0213005X1600080X"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2016.02.010","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2016.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}